Displaying drugs 9951 - 9975 of 12145 in total
PF-05180999
PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999).
Investigational
Matched Description: … a Modified-Release Formulation of PF-05180999). ... is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of …
D-3082-L
D-3082-L is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.
Investigational
Matched Description: … D-3082-L is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide …
PF-03187207
PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. The development of abnormally high IOP, due to blockage...
Investigational
Matched Description: … of fluid in the eye, is believed to be one of the principal causes of glaucoma. ... The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount ... PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of …
2-Hydroxyestradiol
2-Hydroxyestradiol is classified as an endogenous steroid, catechol estrogen, and metabolite of estradiol. It is also a positional isomer of estriol.
Experimental
Matched Description: … It is also a positional isomer of estriol. [A31630] ... 2-Hydroxyestradiol is classified as an endogenous steroid, catechol estrogen, and metabolite of estradiol …
Modithromycin
Modithromycin is under investigation in clinical trial NCT00270517 (Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia).
Investigational
Matched Description: … Another Antibiotic in the Treatment of Community Acquired Pneumonia). ... Modithromycin is under investigation in clinical trial NCT00270517 (Comparative Study of EDP-420 Versus …
BNT111
BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
Investigational
Matched Description: … It consists of a fixed combination of mRNA-encoded, tumor-associated antigens. …
L-erythro-7,8-dihydrobiopterin
7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.
Experimental
Matched Description: … 7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes ... the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde. …
Camrelizumab
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
Investigational
Matched Description: … ED-SCLC After Failure of First Line Standard Therapy). ... is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of …
RSV-604
RSV-604 is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.).
Investigational
Matched Description: … Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.). ... is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of …
Foralumab
Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Investigational
Matched Description: … Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab …
Tilsotolimod
Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)).
Investigational
Matched Description: … With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)). ... Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination …
Cyamemazine
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
Experimental
Matched Description: … class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. ... Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine ... actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of …
Etesevimab
Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.[L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with bamlanivimab to treat mild to moderate COVID-19 in adults and pediatric patients who...
Investigational
Matched Description: … [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID- …
N-(2-Aminoethyl)-1-aziridineethanamine
First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease and its activity against Severe Acute Respiratory Syndrome (SARS).
Experimental
ADH-1
Adherex's biotechnology compound, ADH-1, targets N-cadherin, a protein present on certain tumor cells and established tumor blood vessels. ADH-1 is currently in clinical development in a combination program with a range of chemotherapeutic agents to investigate the synergistic effects noted in our preclinical models. At the end of 2006, the...
Investigational
Matched Description: … Phase II trials of ADH-1. ... ADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors ... causing angiolysis (disruption of blood vessels) and tumor damage. …
CRx-139
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Matched Description: … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting ... This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases. ... It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid …
Mitoquinone
Mitoquinone is based on a novel technology, targeted lipophilic cations, that transport and concentrate antioxidants into the mitochondria -- organelles inside cells that provide energy for life processes -- where they accumulate up to a thousand fold. In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct...
Investigational
Matched Description: … the sporadic form of Parkinson's disease. ... link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease. ... In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular …
Leptin
Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of...
Investigational
Matched Description: … type 2 diabetes are resistant to the effects of insulin. ... These people are said to be resistant to the effects of leptin, in much the same way that people with ... signal that reduces appetite, in general, obese people have an unusually high circulating concentration of …
Shark liver oil
Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight. The 3 main targeted species are the deep sea shark (Centrophorus squamosus), the dogfish (Sqaulus acanthias), and the basking shark (Cetorhinus maximus). Shark oil is a rich source of...
Experimental
Matched Description: … Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body ... Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated ... However the major component is considered to be squalene, which may range up to 90% of the shark oil, …
rhMBL
rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL). Over 10 percent of the general population is estimated to be MBL-deficient. Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide...
Investigational
Matched Description: … in individuals with low levels of Mannose-Binding Lectin (MBL). ... Over 10 percent of the general population is estimated to be MBL-deficient. ... Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide chains. …
Gold
A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Experimental
Matched Description: … Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts. ... It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. …
Froniglutide
Glymera is under investigation in clinical trial NCT01658501 (Phase 2b Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM).
Investigational
Matched Description: … Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM). ... Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of …
Aminocandin
Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms.
Investigational
Matched Description: … and metabolic status of Candida albicans cells within biofilms. ... Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology …
Veltuzumab
Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
Investigational
Matched Description: … for the treatment of non-Hodgkin's lymphoma. ... Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials …
PF-04937319
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Matched Description: … Different Formulations Of PF-04937319 In Healthy Subjects). ... 04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of …
Displaying drugs 9951 - 9975 of 12145 in total